Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery

Journal of Clinical Oncology

Volumn 31, Issue 31, 2013, Pages 4026-4027

  Doolittle, Nancy D ^a   Dósa, Edit ^a,b   Fu, Rongwei ^a   Muldoon, Leslie L ^a   Maron, Leeza M ^a   Lubow, Meredith A ^a   Tyson, Rose Marie ^a   Lacy, Cynthia A ^a   Kraemer, Dale F ^c   Butler, Robert W ^a   Neuwelt, Edward A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; ANTINEOPLASTIC AGENT;

ADULT; ATTENTION; BLOOD BRAIN BARRIER; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVOR; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; EXECUTIVE FUNCTION; HUMAN; INFORMATION PROCESSING; LEARNING; LETTER; MAJOR CLINICAL STUDY; MIDDLE AGED; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESERVATION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; VERBAL MEMORY; WECHSLER INTELLIGENCE SCALE; CENTRAL NERVOUS SYSTEM TUMOR; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; FEMALE; LYMPHOMA; MALE; STATISTICS; SURVIVOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMICALLY INDUCED; COGNITION DISORDERS; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COGNITION DISORDERS; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SURVIVORS;

EID: 84891592987     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.7747     Document Type: Letter

References (8)

1. Neuwelt EA, Goldman DL, Dahlborg SA, et al: Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol 9:1580-1590, 1991
2. Angelov L, Doolittle ND, Kraemer DF, et al: Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: A multi-institutional experience. J Clin Oncol 27:3503-3509, 2009
3. Doolittle ND, Korfel A, Lubow MA, et al: Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 81:84-92, 2013
4. Correa DD, Maron L, Harder H, et al: Cognitive functions in primary central nervous system lymphoma: Literature review and assessment guidelines. Ann Oncol 18:1145-1151, 2007 (Pubitemid 47244358)
5. Meyers CA, Brown PD: Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24:1305-1309, 2006 (Pubitemid 46622034)
6. Vardy J, Rourke S, Tannock IF: Evaluation of cognitive function associated with chemotherapy: A review of published studies and recommendations for future research. J Clin Oncol 25:2455-2463, 2007 (Pubitemid 46999217)
7. Abrey LE: The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors. J Neurooncol 108:285-290, 2012
8. Batchelor TT: Flying solo: Chemotherapy without radiation for primary CNS lymphoma. J Clin Oncol 31:3051-3053, 2013